
Fairchem OrganicQ1 FY25
Fairchem Organic Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹665.4P/E: 34.2Market Cap: ₹838 Cr
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Fairchem Organics showed a 3% year-on-year revenue growth in Q1 FY25, with Rs. 165 crores in revenue.
- EBITDA grew significantly by 86% year-on-year, indicating improving profitability.
- Isostearic acid, a novel high-value product, is expected to drive future growth, with exports to Europe and US already underway.
- Customer stability testing for Isostearic acid takes 3-6 months; approvals from 15-20 new customers are in progress.
- Full capacity utilization for Isostearic acid (500 MT per quarter) is targeted by December 2024.
- New product launches from novel raw materials are in pilot stages, with potential commercial launch around Q4 FY25, though timelines are tentative.
- Management remains optimistic about Isostearic acid growth, focusing efforts primarily on this product segment.
- Total sales volumes remain steady, with Q1 FY25 at 16,728 MT, comparable to previous quarters.
See what Fairchem Organic management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or planned fundraising through debt or equity in the transcript.
- The management did not discuss any plans for raising capital during the Q1 FY 2025 earnings call.
- The focus was primarily on operational highlights, sales performance, and product development, especially the Isostearic acid business.
- Any future updates, including on fundraising, may be communicated in subsequent con-calls or announcements once decisions are made.
- Investors are encouraged to reach out to the company or Investor Relations advisors for further queries.
See what Fairchem Organic management said on order book — free account, 30 seconds.
Capex plans
Yes- No specific mention of current or future capex, capital investment, or strategic investment was made during the call.
- The company is focusing on developing and stabilizing the Isostearic acid business, which involved startup losses earlier but is now operational and exporting.
- Work is ongoing at the pilot plant level for new products derived from new raw materials, with no definite timeline yet for commercial launch; updates will be provided after pilot runs.
- The company is prioritizing Isostearic acid development due to its strong potential but did not disclose any explicit capital expenditure plans related to this or other expansions.
Track Fairchem Organic — get its next earnings analysis in your feed
How does Fairchem Organic rank vs peers in ?
Pro featureThisFairchem Organic
Rev 3Mar 3